GLP-1 drugs are genuinely one of the most significant medical developments in decades. I want to give you a fair read on them — which means being honest about both the evidence and the gaps.
What GLP-1 means
GLP-1 stands for glucagon-like peptide-1. It’s a hormone your small intestine naturally produces after you eat. It does several things:
- Signals your pancreas to release insulin (which lowers blood sugar)
- Signals your pancreas to slow down glucagon release (which raises blood sugar)
- Slows stomach emptying, so food moves through you more gradually
- Signals your brain’s appetite centers that you’re full
The GLP-1 drugs — semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) — mimic or amplify this hormone. They work by binding to the same receptors your natural GLP-1 binds to, but they’re engineered to stay active much longer. Natural GLP-1 lasts only 1–2 minutes. Semaglutide lasts about a week.
What the clinical trials actually showed
Semaglutide (Wegovy) for weight loss: In the STEP 1 trial (2021), 1,961 adults with obesity but no diabetes took 2.4mg semaglutide weekly for 68 weeks. Average weight loss: 14.9% of body weight, compared to 2.4% in the placebo group. That’s roughly 35 pounds on a 235-pound person.
Tirzepatide (Zepbound) for weight loss: In the SURMOUNT-1 trial (2022), participants lost up to 22.5% of body weight at the highest dose — the largest effect size ever seen in a pharmacological weight loss trial.
These are genuinely large numbers. The drugs work.
What happens when you stop
This is the part most news coverage skips.
In a 2022 follow-up study published in Diabetes, Obesity and Metabolism, participants who stopped semaglutide after 68 weeks regained, on average, two-thirds of the weight they’d lost within one year. Blood pressure, cholesterol, and blood sugar markers mostly returned to their pre-drug levels.
This doesn’t mean the drugs are useless — it means they appear to require ongoing use for sustained effect, similar to how blood pressure medication only works while you take it.
The implication: for most people, this is a long-term commitment, not a 6-month reset.
The side effects you should know about
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These affect 30–50% of users and are most common when doses are increased. They tend to improve over time for most people, but not all.
The rarer but more serious concerns:
- Gastroparesis: delayed stomach emptying that persists after stopping the drug, in some patients
- Pancreatitis: rare, but risk appears elevated; don’t use if you have a personal or family history of medullary thyroid cancer or MEN2 syndrome
- Muscle loss: rapid weight loss from any cause can include muscle mass; resistance training while on these drugs appears protective
Who these drugs are (and aren’t) for
The clinical trials primarily enrolled people with BMI ≥ 30 (or ≥ 27 with a weight-related health condition). That’s the population where the data is strongest.
They’re not approved for general weight management in people without those criteria. Off-label prescribing happens, but the risk-benefit calculation looks different.
For people with type 2 diabetes or prediabetes plus significant obesity: the evidence is compelling, and the cardiovascular outcomes data for semaglutide (the SELECT trial) shows real heart protection benefits. For someone wanting to lose 15 pounds who is otherwise healthy: much harder to justify.
The telehealth angle
Compounded semaglutide and tirzepatide became widely available through telehealth platforms when brand-name drugs were on the FDA shortage list. As of late 2026, that status is changing — tirzepatide was removed from the shortage list in 2024, and semaglutide’s status has evolved.
This matters because FDA shortage-list status determines whether compounding pharmacies can legally produce these compounds. If you’re using a telehealth platform for compounded GLP-1s, verify that the program is legally operating given current FDA guidance.
I maintain a comparison page for the programs I’ve vetted here.
Questions worth asking your doctor
If you’re considering these medications:
- What’s the realistic target — weight, A1C, or both?
- How long do you expect me to stay on it?
- What monitoring will we do (thyroid, pancreatic enzymes)?
- If I lose weight and then stop, what’s the plan?
This content is for educational purposes only and is not medical advice. GLP-1 medications require a prescription and medical evaluation. Do not start or stop any prescription medication without consulting your healthcare provider.
